Read by QxMD icon Read


Amany Ali, Heba Sayed, Mohamed Salem, Mohamed Hamdy, Amro Farok
BACKGROUND: Malignant ovarian germ cell tumors (MOGCTs) are rare and represent 1-1.5% of all cancers in children and adolescents. The aim of this study is to analyze the clinicopathological pattern at presentation and management and outcome of MOGCTs in children and adolescents. PATIENTS AND METHODS: Retrospective study included all girls diagnosed with MOGCTs between January 2005 and January 2015 in Pediatric and Surgical Oncology Departments at South Egypt Cancer Institute, Assiut University...
September 1, 2017: Journal of Pediatric Surgery
Ning Zhang, Ruifang Chen, Keqin Hua, Ying Zhang
BACKGROUND: To retrospectively investigate reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors (MOGCT) and sex cord-stromal tumors (SCST). METHODS: Data from 32 MOGCT (6 dysgerminomas, 6 yolk sac tumors, 17 immature teratomas, and 3 mixed germ cell tumors) and 9 SCST (4 granulosa cell tumors and 5 sertoli-leydig cell tumors) aged from 18 to 35, treated in the Obstetrics and Gynecology Hospital of Fudan University from October 2003 to October 2013 were collected and analyzed...
July 27, 2017: Journal of Ovarian Research
Olesya Solheim, Mette Førsund, Claes G Tropé, Sigrid Marie Kraggerud, Jahn M Nesland, Ben Davidson
The purpose of this study was to determine the expression and potential clinical role of epithelial-to-mesenchymal transition (EMT)-related factors in malignant ovarian germ cell tumors (MOGCT). Protein expression of E-cadherin, N-cadherin, P-cadherin, Zeb1, HMGA2, and vimentin by immunohistochemistry was analyzed in 42 MOGCT from patients treated in Norway during the period 1981-2001. Expression was analyzed for association with clinicopathologic parameters. E-cadherin (p = 0.016) and HMGA2 (p = 0.002) expression was significantly higher in immature teratomas and yolk sac tumors compared with dysgerminomas...
September 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
Wenyan Xu, Yanfang Li
OBJECTIVE: The aim of the study was to investigate whether omentectomy (OMT) is necessary in the operation for apparently early stage malignant ovarian germ cell tumors (MOGCTs). METHODS AND MATERIALS: Searching medical records database of Sun Yat-sen University Cancer Center from January 1, 1966, to November 30, 2015, patients with MOGCTs were identified and their age, year of diagnosis, tumor grade, histologic subtype, International Federation of Gynecology and Obstetrics stage, nodal findings, gross observation of omentum, and performance of OMT were assessed...
September 2017: International Journal of Gynecological Cancer
M Terenziani, G Bisogno, R Boldrini, G Cecchetto, M Conte, L Boschetti, M D De Pasquale, D Biasoni, A Inserra, F Siracusa, M E Basso, F De Leonardis, D Di Pinto, F Barretta, F Spreafico, P D'Angelo
OBJECTIVE: Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity. The aim of this study was to assess the outcomes of pediatric patients with MOGCT. METHODS: Patients were treated according to their stage: surgery and surveillance for stage I; a modified bleomycin-etoposide-cisplatin (BEP) regimen for stages II (three cycles), III, and IV (three cycles) with surgery on residual disease...
November 2017: Pediatric Blood & Cancer
Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
OBJECTIVE: To evaluate the oncologic and reproductive outcomes and to analyze prognostic factors after fertility-sparing surgery in patients with early and advanced malignant ovarian germ cell tumors (MOGCTs). METHODS: This study included 171 patients who underwent fertility-sparing surgery. Data were gathered from patients' medical records. Survival analysis was performed using the log-rank test and Cox's proportional hazards model. Reproductive outcomes were analyzed...
June 2017: Gynecologic Oncology
Jakob Skalleberg, Olesya Solheim, Sophie D Fosså, Milada Cvancarova Småstuen, Terje Osnes, Per Ole M Gundersen, Marie Bunne
OBJECTIVE: Evaluate long-term cisplatin-induced ototoxicity in women treated for malignant ovarian germ cell tumors (MOGCT). METHODS: Seventy-four women treated for MOGCT in Norway (1980-2009) were analyzed: 41 had received cisplatin-based chemotherapy (CBCT) ("Cases") and 33 had no CBCT ("Controls"). Median follow-up was 15years. Hearing was assessed by pure tone audiometry and by the SCIN questionnaire. Air conduction thresholds were reported as absolute hearing thresholds and age-adjusted thresholds...
April 2017: Gynecologic Oncology
G Mangili, C Sigismondi, D Lorusso, G Cormio, M Candiani, G Scarfone, F Mascilini, A Gadducci, A M Mosconi, P Scollo, C Cassani, S Pignata, G Ferrandina
Background: Surgery followed by platinum-based chemotherapy is the standard of care for MOGCTs, except for stage IA dysgerminoma and stage IA grade 1 immature teratoma where surveillance only is recommended. The role of adjuvant chemotherapy and surgical staging is debated. Patients and methods: Data from 144 patients with stage I MOGTs were collected among MITO centers (Multicenter Italian Trials in Ovarian Cancer) and analyzed. Results: Fifty-five (38...
February 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Ting Zhao, Yan Liu, Hongyuan Jiang, Hao Zhang, Yuan Lu
Bilateral malignant ovarian germ cell tumors (MOGCTs) are rare. Determination of the optimal treatment modalities is crucial, as these malignancies mainly affect girls and young women who may wish to preserve their fertility. In order to review the prevalence, clinical characteristics, treatment and outcome of bilateral MOGCTs, we performed a retrospective review of patients who were diagnosed with bilateral MOGCTs and underwent primary surgery at the Obstetrics and Gynecology Hospital of Fudan University (Shanghai, China) between January, 2001 and December, 2014...
August 2016: Molecular and Clinical Oncology
Jin Li, Xiaohua Wu
The necessity and extent of comprehensive surgical staging (CSS) and lymphadenectomy in the treatment of malignant ovarian germ cell tumors (MOGCTs) is still controversial. However, it is uniformly agreed that CSS with lymphadenectomy is crucial to follow up patients without adjuvant chemotherapy in stage I MOGCTs. Considering the chemotherapy-sensitive nature of MOGCTs, fertility-sparing cytoreductive surgery (FSCS) seems a reasonable approach in initial treatment for patients with advanced stage. When encountered with bilateral MOGCTs, debulking is surely granted if there is no desire for fertility...
August 2016: Current Treatment Options in Oncology
Ting Zhao, Hao Zhang, Yan Liu, Hongyuan Jiang, Xiao Wang, Yuan Lu
BACKGROUND: Malignant ovarian germ cell tumours (MOGCTs) are usually detected at an early stage, with patients achieving a satisfactory prognosis. However, the role of staging surgery in the treatment of apparent early-stage MOGCTs remains controversial. AIMS: To investigate the role of staging procedures in apparent early-stage patients. MATERIALS AND METHODS: We performed a retrospective review of 102 patients who were diagnosed with MOGCTs and had malignant lesions confined to their ovaries, between January 1997 and October 2014 at the Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China...
August 2016: Australian & New Zealand Journal of Obstetrics & Gynaecology
Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
OBJECTIVE: The aim of this study was to evaluate the role of complete surgical staging of a malignant ovarian germ cell tumor (MOGCT) that is apparently confined to the ovaries. METHODS: This retrospective study included 135 patients with stage I MOGCT after surgery. Patients who were categorized with stage I disease without complete staging operation were staged as IX. Statistical analysis was performed using Chi-squared or Fisher's exact tests and a Cox proportional hazards model...
September 2016: Annals of Surgical Oncology
Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
OBJECTIVES: This study aimed to evaluate the safety of surgery alone followed by surveillance in young women with stage I malignant ovarian germ cell tumor (MOGCT). METHODS: A retrospective review was performed on 31 patients with stage I MOGCT who were treated by surgery alone with follow-up. RESULTS: The median patient age was 22 years (range, 6-45 years). The histological type was dysgerminoma in 17, immature teratoma in 11, yolk sac tumor in 1, and mixed MOGCT in 2 cases...
June 2016: International Journal of Gynecological Cancer
Abdul Hannan, Mahim Akmal Malik, Samir Fasih, Farhana Badar, Neelam Siddiqui
BACKGROUND: Malignant Ovarian Germ Cell Tumours (MOGCT) are rare neoplasms and their behavior is unknown in South-East Asian population. METHODS: Case records of 66 patients from 1994-2007 with MOGCT were reviewed. Histology was based on WHO classification. Tumours were staged according to International Federation of Gynecology and Obstetrics (FIGO) system. Data was collected on age, histopathology, stage, alpha-feto protein (AFP) and B-human chorionic gonadotropins (B-hCG) levels, treatment, time to recurrence (TTR) and overall survival (OS)...
July 2015: Journal of Ayub Medical College, Abbottabad: JAMC
Zhi-juan Yang, Zhen-chan Liu, Ren-ji Wei, Li Li
BACKGROUND/AIMS: To analyze the clinicopathological factors that affect the prognosis and fertility of patients with malignant ovarian germ cell tumors (MOGCTs). METHODS: The medical records and follow-up data of 106 patients with MOGCTs who were treated at The Affiliated Tumor Hospital of Guangxi Medical University between January 1986 and December 2010 were enrolled in this study. A Kaplan-Meier analysis was used to analyze the survival curves. The different prognoses among the various clinicopathological factors were evaluated using a univariate analysis and a log-rank test...
2016: Gynecologic and Obstetric Investigation
Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
OBJECTIVE: To analyze the oncologic and reproductive outcomes of pediatric and young adolescents with malignant ovarian germ cell tumors (MOGCTs). METHODS: Pediatric or young adolescent girls aged 16years or under with MOGCT were eligible for this study. RESULTS: Forty-two pediatric or adolescent girls with MOGCT met the inclusion criteria. The median age was 12years (range, 6-16years) and 29 patients were premenarchal. The most common histologic type was immature teratoma, and 30 patients (54...
June 2015: Gynecologic Oncology
Usanee Chatchotikawong, Irene Ruengkhachorn, Chairat Leelaphatanadit, Nisarat Phithakwatchara
PURPOSE: To determine the rate of lymph node metastasis, oncologic and pregnancy outcomes in apparent early-stage malignant ovarian germ cell tumor (MOGCT). MATERIALS AND METHODS: Medical records of apparent early-stage MOGCT patients undergoing primary surgical treatment at Siriraj Hospital, Bangkok, Thailand, between January 2006 and December 2013, were retrospectively reviewed. RESULTS: Thirty-eight patients had apparent stage I-II MOGCT...
2015: Asian Pacific Journal of Cancer Prevention: APJCP
O Solheim, C G Tropé, E Rokkones, J Kærn, T Paulsen, H B Salvesen, B Hagen, A B Vereide, S D Fosså
PURPOSE: By self-report and serum levels of anti-Mullerian hormone (AMH) this study aims to assess post-treatment fertility after modern treatment of women with malignant ovarian germ cell tumors (MOGCT). PATIENTS AND METHODS: In 2013 a questionnaire-based survey was performed in 61 MOGCT patients diagnosed at age <40years from 1980-2009. Forty-nine of them also attended the out-patient clinic. The event of first post-treatment pregnancy ("fertility") was documented as cumulative estimates for all 61 patients and within each of 4 treatment groups: Group 1: Surgery only (n=10); Group 2: ≤3cycles of cisplatin-based chemotherapy (CBCT) (n=20); Group 3: >3cycles of CBCT (n=15) and Group 4: other adjuvant treatment (n=16)...
February 2015: Gynecologic Oncology
Chi-An Chen, Hao Lin, Chia-Sui Weng, Kuo-Chang Wen, Chien-Hsing Lu, Hung-Hsueh Chou, Yu-Fang Huang, Chieh-Yi Kang, Chih-Ming Ho, Mu-Hsien Yu, Cheng-Yang Chou
BACKGROUND: The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed. PATIENTS AND METHODS: Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed...
December 2014: European Journal of Cancer
Jessica Ottolina, Giorgia Mangili, Cristina Sigismondi, Valeria Stella Vanni, Paola Viganò, Massimo Candiani
Germ cell ovarian tumors (malignant ovarian germ cell tumors - MOGCT) affect young women and are treated by surgery plus chemotherapy. It is well known that cytotoxic treatment may accelerate depletion of the primordial follicle pool leading to impaired fertility and premature menopause. Aim of this study is to identify patient candidates for fertility preservation strategies. We report our experience in preservation of fertility for four patients affected by MOGCT, referred to San Raffaele Hospital Oncofertility Unit...
November 2014: Gynecological Endocrinology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"